The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours.
about
Lung cancer staging: clinical and radiologic perspectivesThe impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysisPD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?New TNM classification: achievements and hurdlesThe effect of lysyl oxidase polymorphism on susceptibility and prognosis of nonsmall cell lung cancerLung cancer in Brazil: epidemiology and treatment challenges.Disparities in lung cancer staging with positron emission tomography in the Cancer Care Outcomes Research and Surveillance (CanCORS) study.A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancerThe Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis.Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy.Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.Multidisciplinary Evaluation of Patients With Suspected Lung Cancer.Association between CXCL16/CXCR6 expression and the clinicopathological features of patients with non-small cell lung cancer.Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapyComplement factor H autoantibodies are associated with early stage NSCLC.Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial.Pulmonary atelectasis and survival in advanced non-small cell lung carcinoma.Long-term survival outcomes of video-assisted thoracic surgery for patients with non-small cell lung cancerNational Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specAnalysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system.Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLCPhotodynamic therapy for lung cancer and malignant pleural mesothelioma.National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancerCoincidence between malignant perivascular epithelioid cell tumor arising in the gastric serosa and lung adenocarcinoma.Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trialsEvaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study.Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size.Role of HGF/MET axis in resistance of lung cancer to contemporary management.Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registryClinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancerThe association of adiponectin gene promoter variations with non-small cell lung cancer in a Han Chinese population.Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerHigh mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas.The 7th lung cancer TNM classification and staging system: Review of the changes and implications.Postoperative radiotherapy for elderly patients with stage III lung cancer.Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunitiesTripartite motif-containing 29 as a novel biomarker in non-small cell lung cancerStaging non-small cell lung cancer
P2860
Q24600394-71127B9F-1737-4DF9-A19F-9210D3F694C3Q26741041-F8F8B144-9777-4AF3-AE6A-A51DF5C0EC00Q26741101-0743136B-FBB1-4051-AE5F-CE234E2A53FDQ27022737-B64EB1C2-DDD8-43F7-A556-F09784C82A3DQ28274238-49F99146-2081-4108-9D4B-4EE659C7E6E0Q30235908-AFC2571C-8898-4A1D-A646-C2C8ADF6CD40Q30500194-57F8735D-98F2-4F4C-B56C-72696C1A065DQ30539299-0C94569E-C4C3-4F77-8F9D-4D8B9B53B5F2Q30749009-FB3BE3C9-DC0F-454F-8B0F-C6B084198D86Q30993385-8D941CF7-3C43-4095-A23E-40C791A00096Q33418358-54DE01F9-4B35-469A-899E-C669D1A9E3A7Q33435236-00275DB9-41B1-44EB-A4C0-A0B8421E77A7Q33599661-83A48BEA-760E-471B-939D-61736CA7F17EQ33750972-39B2CD87-E2C7-49AC-842D-D5EB87BC4938Q33922698-4A9973BA-12BB-4110-B474-BBC6023EACE5Q33937882-555E0FEB-2904-4521-BA86-0C5ECDAF93FBQ34041802-EBA8BAE4-4487-4A21-871D-82A15CA969D5Q34128113-4907437A-0A2D-41DC-932A-599FAE907598Q34130262-D5300E39-1681-4770-87C3-015B34D8DC80Q34237215-B28FAFA5-76A0-40F6-A702-8D96B274544CQ34552929-E3FE6804-7D3F-443F-93A7-F85B80F3716CQ34695293-FC2E3287-6A07-423F-8A9D-9EA4A02C937FQ34747440-EF84CC1D-49A2-400D-8945-1AC22ACD7C30Q34763290-DB37B190-DD34-4E3F-893C-FDB9294F5BB1Q35012179-E429904D-B130-47F9-A5E0-1FB904E1788EQ35171942-34C093A7-60BD-4A02-95C7-6B396EBBB872Q35190735-4D8F117A-98AA-4C97-9809-F6CE8086E213Q35194720-DA4FC5F4-BB43-4036-9E93-E15394BA87C3Q35200337-419AFBB0-EE49-4B34-8F77-7104EA9FFE36Q35202454-4200F643-ABC5-4E90-9651-651C20E40655Q35540726-5F98BAC7-8A3C-426C-9B14-A7C514796545Q35644169-6B7E079C-A56B-4030-BE8A-480624B98BBEQ35752978-42E8A81B-66D5-4749-87BE-E42A0F727692Q35793906-C6FCCB75-A482-444F-BB41-94B6772DA28FQ35954065-76F7EB78-1858-4D39-BB99-1F3F9DE9943FQ35957887-BB05F57B-EA30-4759-9E8C-D24FD79E28B4Q35968871-DF4CC289-C864-432E-852B-DDA577F56CD3Q35996028-B9CFAAFE-CBC1-449B-B404-6A8ED4A3E324Q36085398-1055AE06-E754-4792-B7C5-ECF19318C5E1Q36129173-A9DB422B-9FC3-419E-8E32-E7420F2E8A7B
P2860
The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
The IASLC Lung Cancer Staging ...... fication of malignant tumours.
@en
The IASLC Lung Cancer Staging ...... fication of malignant tumours.
@nl
type
label
The IASLC Lung Cancer Staging ...... fication of malignant tumours.
@en
The IASLC Lung Cancer Staging ...... fication of malignant tumours.
@nl
prefLabel
The IASLC Lung Cancer Staging ...... fication of malignant tumours.
@en
The IASLC Lung Cancer Staging ...... fication of malignant tumours.
@nl
P2093
P1476
The IASLC Lung Cancer Staging ...... fication of malignant tumours.
@en
P2093
Cancer Research and Biostatistics
Catherine Kennedy
IASLC International Staging Committee
John J Crowley
Leslie H Sobin
Mark Krasnik
Observers to the Committee
Participating Institutions
Patti A Groome
Peter Goldstraw
P304
P356
10.1097/JTO.0B013E31812D05D5
P577
2007-08-01T00:00:00Z